MICHAEL POWELL
CIK 1202793 · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$78.23M
Companies
14
Total Filings
58
Lifetime Open-Market Net
$87.04M
Filer Profile
Reported Address
3000 SAND HILL ROAD, 4-250MENLO PARK, CA 94025
Related Filers
JAMES HEALY — 57 joint filings, latest 2021-05-18
Anand Mehra — 26 joint filings, latest 2019-11-19
Eric Buatois — 24 joint filings, latest 2016-10-24
SOFINNOVA VENTURE PARTNERS VII L P — 17 joint filings, latest 2015-05-08
Sofinnova Management VII, L.L.C. — 17 joint filings, latest 2015-05-08
Sofinnova Management IX, L.L.C. — 15 joint filings, latest 2020-08-12
Sofinnova Venture Partners IX, L.P. — 15 joint filings, latest 2020-08-12
Sofinnova Management VIII, L.L.C. — 11 joint filings, latest 2018-09-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $22.81 | — | $0 | 2 | 2026-06-10 |
| Galera Therapeutics, Inc. (GRTX) Delisted | Director | — | $17.60 | — | $0 | 5 | 2023-06-16 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Director | — | $10.50 | — | $0 | 4 | 2022-05-31 |
| VERA | 10%+ Owner | 2,187,504 | $35.05 | $76.67M | $32.00M | 1 | 2021-05-18 |
| NXTC | 10%+ Owner | 222,655 | $7.00 | $1.56M | $27.56M | 1 | 2019-11-19 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 38,331 | $0.69 | $26.4K | $0 | 5 | 2019-06-07 |
| Iterum Therapeutics plc (ITRM) Delisted | 10%+ Owner | 81,768 | $0.03 | $2.5K | $26.00M | 1 | 2018-05-30 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | 2,117,669 | — | — | $6.00M | 2 | 2016-09-06 |
| HUMANIGEN, INC (KBIO) Delisted | 10%+ Owner | 39,637 | — | — | $0 | 1 | 2013-02-07 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 9,302 | — | — | $3.98M | 7 | 2012-03-27 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | 10%+ Owner | 51,542 | — | — | -$1.09M | 1 | 2012-01-03 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | 3,236 | — | — | -$22.41M | 13 | 2011-06-06 |
| Molecular Templates, Inc. (THLD) Delisted | Director | — | — | — | $0 | 2 | 2008-05-14 |
| ANESIVA, INC. (ANSV) Delisted | Director | 3,703,769 | — | — | $15.00M | 5 | 2008-05-12 |
Recent Filings · Page 4 of 6
58 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-03-27 | Trius Therapeutics Inc (TSRX) Delisted | Exer (M) | +9,302 | $12.0K | EDGAR |
| 2012-01-20 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −6,900 | -$38.6K | EDGAR |
| 2012-01-17 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −24,622 | -$134.0K | EDGAR |
| 2012-01-17 | Trius Therapeutics Inc (TSRX) Delisted | Other (J) | −3,470,950 | $0 | EDGAR |
| 2012-01-03 | Anthera Pharmaceuticals Inc (ANTH) Delisted | Sell (S) | −175,000 | -$1.09M | EDGAR |
| 2011-06-06 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-06 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-12-23 | Orexigen Therapeutics, Inc. (OREX) Delisted | Sell (S) | −825,000 | -$6.84M | EDGAR |
| 2010-12-21 | Orexigen Therapeutics, Inc. (OREX) Delisted | Sell (S) | −456,254 | -$3.91M | EDGAR |
| 2010-11-05 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.